Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food effect on pharmacokinetics of doravirine/islatravir FDC in healthy Japanese adults
jRCT2031200365Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of doravirine and islatravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: AUC0-inf for doravirine, AUC0-last for doravirine and 16 more. Started Feb 2021; status: completed.
02
Drugs
doravirineislatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on jRCT2031200365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200365.